Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Inventory: 2010-2015

Historic Inventory for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Dec 2015 value amounting to $1,000.

  • Lineage Cell Therapeutics' Inventory fell 99.62% to $1,000 in Q4 2015 from the same period last year, while for Dec 2015 it was $1,000, marking a year-over-year decrease of 99.62%. This contributed to the annual value of $1,000 for FY2015, which is 99.62% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Inventory stood at $1,000 for Q4 2015, which was down 99.62% from $260,000 recorded in Q3 2015.
  • In the past 5 years, Lineage Cell Therapeutics' Inventory registered a high of $299,308 during Q1 2015, and its lowest value of $1,000 during Q4 2015.
  • In the last 3 years, Lineage Cell Therapeutics' Inventory had a median value of $245,078 in 2014 and averaged $185,692.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Inventory spiked by 352.06% in 2014 and then slumped by 99.62% in 2015.
  • Lineage Cell Therapeutics' Inventory (Quarterly) stood at $51,174 in 2011, then climbed by 8.09% to $55,316 in 2012, then skyrocketed by 223.04% to $178,694 in 2013, then spiked by 48.86% to $266,000 in 2014, then tumbled by 99.62% to $1,000 in 2015.
  • Its last three reported values are $1,000 in Q4 2015, $260,000 for Q3 2015, and $297,000 during Q2 2015.